RAL in the treatment of advanced stage endometriosis between 2008 and 2015 have been reviewed. Some search terms, such as "robotic", "laparoscopic", "endometriosis" "severe endometriosis" "advanced stage endometriosis", and "laparoscopic endometriosis", were used. The "related articles" offered by databases were explored to broaden the search, and all abstracts, studies, and citations were reviewed as well. A manual search was also carried out to identify trials for possible inclusion as a supplement. Studies in English language were considered for inclusion. The latest date for this search was on Mar 30 th , 2015. Data extractionTwo of the present authors (Shao-Hui Chen, Zhao-Ai Li) reviewed relevant articles and extracted the specific studies on comparing CL with RAL. If disagreements about inclusion existed, a third reviewer (Xiu-Ping Du) was asked to assess the articles involved until obtaining a consensus. The quality of each study was
BackgroundThe present COVID-19 pandemic has tended toward normality. To provide convenient, safe, and effective home treatment programs for patients with recurrent ovarian cancer (ROC), the clinical efficacy and safety of poly (ADP-ribose) polymerase inhibitor (PARPi) (including olaparib, niraparib, and rucaparib) monotherapy as a maintenance treatment for platinum-sensitive ROC were systematically evaluated.MethodsNumerous electronic databases were systematically searched for randomized controlled trials (RCTs) of PARPi maintenance treatment for ROC that were published before June 2021. The primary endpoints were overall survival (OS) and progression-free survival (PFS), and the secondary endpoint was grade 3-4 adverse effects (AEs). After data extraction and the quality evaluation of the included studies, Bayesian network meta-analysis (NMA) was performed using R software. The ability of each treatment was ranked using the surface under the cumulative ranking (SUCRA) curve.ResultsThe analysis included five studies and 1390 patients. The NMA results demonstrated that compared with the placebo, olaparib and niraparib exhibited significant benefits in the gBRCA-mutated population, and respectively reduced the risk of death by 31% (HR = 0.69, 95% CI: 0.53-0.90) and 34% (HR = 0.66, 95% CI: 0.44-0.99). Olaparib, niraparib, and rucaparib were all found to be very effective in prolonging PFS in patients with ROC. All three PARPi treatments increased the number of grade 3-4 AEs in patients with ROC as compared with the placebo.ConclusionsOverall, olaparib and niraparib maintenance treatment can significantly prolong the OS of patients with gBRCA mutations. Furthermore, the three investigated PARPi monotherapy maintenance treatments can prolong PFS regardless of BRCA mutation status. Although the incidence of AEs in the treatment groups was found to be significantly higher than that in the placebo group, the patients in the treatment group tolerated the treatment. Home oral PARPi treatment can balance tumor treatment and pandemic prevention and control, and is the most convenient, safe, and effective home treatment method available against the background of the current COVID-19 pandemic. Systematic Review Registrationhttps://inplasy.com/inplasy-2021-6-0033/.
8585 Background: AL8326 is a novel, orally administered, small molecule tyrosine kinase inhibitor (TKI). The primary objective of this Phase Ib/IIa study is to evaluate the safety and efficacy of AL8326 monotherapy in patients with ≥3rd line small cell lung cancer (SCLC) treatment. Methods: Patients with a diagnosis of small cell lung cancer either limited or extended stage requiring third or further line treatment were eligible for enrollment. The regimen was a 28-day cycle with oral AL8326 administered at 60 mg once per day via RECISIT1.1 evaluation until disease progression (PD), or intolerable toxicity or any other reason discontinuations. Results: At the cut-off date Nov 30, 2022, total n = 30 patients were enrolled. The objective response rate (ORR) was 20% (6/30) (4 confirmed). The disease control rate (DCR) was 56.7% (17/30). Median progression-free survival (PFS) was 3.65 months (95% CI: 1.9 – 5.5) and median overall survival (OS) was 10.42 months (95% CI: 5.4, NE). The median duration of response (DOR) was 5.6months. All 30 subjects had reported AE at least once. Common treatment emergent adverse events (TEAE) were similar to other TKI drug and included (incidence ≥20%): thyroid stimulating hormone (TSH) increase (46.67%), proteinuria (43.33%), weight loss (40.00%), hypertension (36.67%), thrombocytopenia (33.33%), diarrhea (33.33%), positive fecal occult blood (30.00%), hypercholesterolemia (26.67%), hypertriglyceridemia (26.67%), hand- foot syndrome (HFS) (20.00%), loss of appetite (20.00%). Most of these AEs were grade 1-2 (CTCAE V5.0). Conclusions: AL8326 has demonstrated acceptable tolerability and positive efficacy on small cell lung cancer treatment. A US Phase 2 (NCT05363280) study is ongoing and a phase 3 study is in preparation. Clinical trial information: NCT04890795 .
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.